Adjuvant Combination Chemotherapy in Node-Positive Breast Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Phase III Randomized Study of Adjuvant CA (Cyclophosphamide/Doxorubicin) Comparing Standard- vs Intermediate- vs High-Dose Doxorubicin, with vs without Subsequent Paclitaxel, in Women with Node-Positive Breast Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentClosedover 18NCICLB-9344
E-C9344, NCCTG-943051, SWOG-9410, INT-0148

Trial Description


Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without paclitaxel in treating women who have breast cancer.


Final eligibility for a clinical trial is determined by the health professionals conducting the trial.


Patients will be randomly assigned to receive one of three different doses of doxorubicin plus cyclophosphamide for 3 months. Within each of these groups, patients will be further randomized to receive either 3 additional months of chemotherapy with paclitaxel or no further treatment. Some patients from all groups will also receive tamoxifen by mouth once a day for 5 years. Patients will be evaluated every 3 months for 1 year, every 6 months for 2 years, and once a year thereafter.


For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Cancer and Leukemia Group B

I. Craig Henderson, MD, Protocol chair
Ph: 415-353-7070; 800-888-8664

Eastern Cooperative Oncology Group

Lori Goldstein, MD, Protocol chair
Ph: 215-728-2689; 888-369-2427

Southwest Oncology Group

Silvana Martino, DO, Protocol chair
Ph: 310-582-7900

North Central Cancer Treatment Group

James Ingle, MD, Protocol chair
Ph: 507-284-3731